Sarah Aebersold Sells 5,771 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 5,771 shares of BioLife Solutions stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $130,770.86. Following the transaction, the insider now owns 80,094 shares in the company, valued at approximately $1,814,930.04. This represents a 6.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The shares were sold at an average price of $25.44, for a total transaction of $68,560.80.
• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total value of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Price Performance

Shares of BLFS stock traded down $1.34 on Thursday, hitting $22.44. 591,144 shares of the stock traded hands, compared to its average volume of 358,590. The firm has a 50 day simple moving average of $26.11 and a two-hundred day simple moving average of $25.54. BioLife Solutions, Inc. has a 52 week low of $14.84 and a 52 week high of $29.55. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -21.17 and a beta of 2.04. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same quarter last year, the business earned ($0.21) EPS. As a group, equities research analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently modified their holdings of the business. Invesco Ltd. grew its stake in BioLife Solutions by 1.1% during the 4th quarter. Invesco Ltd. now owns 3,239,469 shares of the medical equipment provider’s stock worth $84,097,000 after buying an additional 36,176 shares during the last quarter. Fred Alger Management LLC lifted its holdings in shares of BioLife Solutions by 1.0% during the fourth quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider’s stock worth $41,386,000 after purchasing an additional 16,274 shares during the period. State Street Corp boosted its holdings in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after purchasing an additional 95,788 shares during the last quarter. Millennium Management LLC boosted its position in BioLife Solutions by 49.1% in the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after purchasing an additional 377,111 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in BioLife Solutions by 4.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 887,008 shares of the medical equipment provider’s stock valued at $23,028,000 after buying an additional 40,416 shares during the period. 93.24% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BLFS has been the topic of several recent research reports. StockNews.com lowered BioLife Solutions from a “hold” rating to a “sell” rating in a report on Monday. HC Wainwright increased their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. KeyCorp raised their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Northland Securities increased their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Finally, Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.